Scarica l'app Stockscreener
1.28
7.25%
-0.10
Pre-mercato:
1.26
-0.02
-1.56%
Precedente Chiudi:
$1.38
Aprire:
$1.37
Volume 24 ore:
482.64K
Relative Volume:
0.04
Capitalizzazione di mercato:
$10.77M
Reddito:
-
Utile/perdita netta:
$-16.42M
Rapporto P/E:
-0.0549
EPS:
-23.3189
Flusso di cassa netto:
$-6.75M
1 W Prestazione:
+5.79%
1M Prestazione:
+0.79%
6M Prestazione:
-85.92%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.27
$1.37
Intervallo di 1 settimana:
$1.1601
$1.401
Portata 52W:
$0.575
$23.13
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Nome
Silexion Therapeutics Corp
Settore
Industria
Telefono
972-8-6286005
Indirizzo
12 ABBA HILLEL ROAD, RAMAT GAN
Confronta SLXN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.28 | 10.77M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
Silexion Therapeutics reaches deal to retire convertible note - Investing.com
Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks
Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal
Silexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer - Benzinga India
Silexion Therapeutics Reports Positive Data for SIL204 - TipRanks
Silexion reports initial data from systemic administration of SIL204 - TipRanks
Silexion Therapeutics Reports Positive Efficacy Data for SIL204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - StreetInsider.com
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - GlobeNewswire
Can Silexion's New Pancreatic Cancer Drug Stop Metastasis? Early Data Shows 80% Tumor Reduction - StockTitan
Can Silexion's RNAi Therapy Revolutionize Pancreatic Cancer Treatment? March Data Will Tell - StockTitan
Is Now The Time To Buy Silexion Therapeutics Corp (NASDAQ: SLXN) Stock? - Stocks Register
Silexion completes study of SIL-204 in orthotopic pancreatic cancer models - BioWorld Online
Silexion completes initial study of SIL-204 in pancreatic cancer models - TipRanks
Silexion Therapeutics Completes Initial Study of SIL-204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics Announces Completion of Initial Study - GlobeNewswire
Can Silexion's RNA Therapy Change Pancreatic Cancer Treatment? Key Study Completed - StockTitan
Comparing Silexion Therapeutics (NASDAQ:SLXN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
SLXN’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Silexion Therapeutics Corp (NASDAQ:SLXN) Stock Is up 127.83% From Its Low, This Stock Is Just Warming Up - Stocks Register
A Deep Dive into Silexion Therapeutics Corp (SLXN) Stock Performance - The InvestChronicle
Silexion Therapeutics Corp (SLXN) Stock: A Review of the Recent Movement - The News Heater
Investor’s Toolkit: Key Ratios for Assessing Silexion Therapeutics Corp (SLXN)’s Performance - The Dwinnex
A Look at Silexion Therapeutics Corp (SLXN) Shares in the Recent Past Indicates Growth - SETE News
why Silexion Therapeutics Corp [SLXN] is a Good Choice for Investors After New Price Target of $9.00 - The DBT News
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
The time has not yet come to remove your chips from the table: Silexion Therapeutics Corp (SLXN) - SETE News
Next-generation siRNA successfully silences multiple KRAS mutations - BioWorld Online
How analysts predict Silexion Therapeutics Corp (SLXN) will perform this quarter? - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why - Asianet Newsable
Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds - MSN
3 Penny Stocks to Watch Now, 1/30/25 - TipRanks
Dow Jumps Over 100 Points; Tesla Earnings Miss Views - Benzinga
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds - GlobeNewswire
Cancer Drug Developer Silexion Raises Millions in Clever Financial MoveHere's the Deal - StockTitan
Stock market news: Signing Day Sports +124.23%, Silexion Therapeutics +80.74% among top gainers during mid day trading - Business Upturn
Stock market today: Signing Day Sports +200.52%, Silexion Therapeutics +69.63% among top gainers in early trading - Business Upturn
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market - Yahoo Finance
Silexion (SLXN) Stock Rallies In Pre-Hour Market Amid Promising Study Results - Stocks Telegraph
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion Therapeutics Corp. Announces $3.3 Million Warrant Exercise and New Private Placement Financing - Nasdaq
Silexion reports breakthrough in KRAS cancer therapy By Investing.com - Investing.com Canada
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday? - AOL
Gold Gains 1%; Boeing Shares Rise Following Q4 Results - Benzinga
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results - Benzinga
Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate - Marketscreener.com
Silexion reports breakthrough in KRAS cancer therapy - MSN
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
Silexion Therapeutics Corp Azioni (SLXN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):